Devil's Claw (Sengaparile, Harpagophytum procumbens)

Harpagoside, an iridoid glycoside, is the marker compound and the basis of standardisation, though it is probably not the only active constituent. In laboratory work harpagoside and related iridoids suppress NF-kappaB activation and reduce COX-2 and iNOS expression, which would plausibly dampen inflammatory pain. Whether enough harpagoside survives gastric hydrolysis and reaches joint tissue at ordinary doses is not well established, and the gap between the cell-culture mechanism and the modest clinical results has never been closed.

Most of the published research on this comes from one place. 100% of it is from Kalahari sands of Namibia, Botswana and northern South Africa, exported since the 1950s to Germany, which remains the largest market. Findings that no unrelated group has reproduced are weaker than the study count makes them look.

The plant's names divide along what people noticed about it. Southern African names such as sengaparile and otjihangatene attach to the tuber and its use, while the European names, duiwelsklou, Teufelskralle, grapple plant, all describe the barbed fruit that catches in animals' feet, which is what a traveller sees first. The botanical genus name Harpagophytum makes the same observation in Greek, from harpagos, a grappling hook. A second and more consequential lineage problem sits in the trade rather than the language: since the 1970s commercial devil's claw has been drawn from both H. procumbens and the lower-harpagoside H. zeyheri, frequently mixed, so pharmacopoeial identity, label species and capsule contents have never quite converged.

Indigenous knowledge of the tuber long precedes the written record. Lübbert published on its uses in 1901 and Hellwig followed in 1907, both drawing on southern African informants. The story most often retold, that the farmer and soldier Gottreich Hubertus Mehnert learned of the plant from a local healer during the Nama and Herero wars of 1904 to 1908, has been treated sceptically by later historians, who read it as marketing romance grafted onto a much older San and Tswana pharmacopoeia. Its route into European medicine ran through the botanist O. H. Volk, interned in South West Africa during the Second World War, who met Mehnert in captivity, brought the plant to German attention on his return, and passed it to the researcher Zorn, whose work in the 1950s began the modern investigation. German firms built the export trade from there.

1. 1901Lübbert publishes on southern African medicinal uses of Harpagophytum, the earliest substantial European record.
2. 1907Hellwig documents further traditional applications of the tuber.
3. 1904 to 1908The period in which Gottreich Hubertus Mehnert is said to have learned of the plant from a healer, a story later historians treat as embellished.
4. 1950sO. H. Volk brings the plant to German scientific attention after wartime internment in South West Africa; Zorn's laboratory work begins the modern research line.
5. 1975Namibia's Nature Conservation Ordinance makes both Harpagophytum species permit-controlled for collection, transport, possession and sale.
6. 2000Germany proposes listing H. procumbens on CITES Appendix II at CoP11; range states object on livelihood grounds and no listing is adopted.
7. 2004Gagnier, Chrubasik and Manheimer publish the first systematic review; the CITES Plants Committee continues reviewing the species without listing it.
8. 2014The Cochrane review of herbal medicine for low back pain grades the devil's claw evidence as low quality.
9. 2016The EMA adopts its revised herbal monograph, registering the root for traditional use only.

For San and Tswana communities the tuber is sengaparile, dug in the wet season when the plant's above-ground growth reveals where the roots lie. Traditional applications ran wider than joints: decoctions for fever, malaria, indigestion and blood diseases, ointments for sores and boils, and preparations used by women in childbirth and afterwards. Harvesting is still overwhelmingly done by hand, largely by rural women in their forties to sixties, using a digging stick to follow the lateral roots out from the parent plant.

Key compound

Harpagoside (an iridoid glycoside), 0 to 4% in H. procumbens

Part used

Secondary storage tuber, not the parent root

Namibian export scale

Roughly 700 metric tons a year (2015 to 2020 average)

Regulatory status (EU)

EMA traditional-use monograph for minor joint pain, 2016

What follows is unfinished work on our side, not a finding about Devil's Claw (Sengaparile, Harpagophytum procumbens). A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• What people take it for. We have not catalogued the claims made for it.